Judgment of the Court (First Chamber), 6 December 2012

AstraZeneca AB and AstraZeneca plc v European Commission

Appeal — Competition — Abuse of dominant position — Market in anti-ulcer medicines — Abuse of procedures relating to supplementary protection certificates for medicinal products and of marketing authorisation procedures for medicinal products — Misleading representations — Deregistration of marketing authorisations — Obstacles to the marketing of generic medicinal products and to parallel imports

Case C‑457/10 P



Top of the page Documents in the Case
Document Date Name of the parties Subject-matter Curia EUR-Lex
Judgment (OJ)
11/01/2013 AstraZeneca v Commisson
View pdf documents
Judgment
ECLI:EU:C:2012:770
06/12/2012 AstraZeneca v Commisson
EUR-Lex text EUR-Lex bilingual text
Judgment (Summary)
ECLI:EU:C:2012:770
06/12/2012 AstraZeneca v Commisson
Opinion
ECLI:EU:C:2012:293
15/05/2012 AstraZeneca v Commisson
EUR-Lex text EUR-Lex bilingual text
Application (OJ)
06/11/2010 AstraZeneca v Commisson
View pdf documents
Top of the page Legal analysis of the decision or of the case

Reports of Cases

published in the electronic Reports of Cases (Court Reports - general)

Subject-matter

Appeal brought against the judgment of the General Court (Sixth Chamber, extended composition) of 1 July 2010 in Case T321/05 AstraZeneca v Commission, in which the General Court annulled, in part, the Commission Decision of 15 June 2005 relating to a proceeding under Article 82 EC and Article 54 EEA (Case COMP/A.37.507/F3 – AstraZeneca) which imposed a fine of EUR 60 million on the applicants for abusive use of the patent system and the procedure for placing pharmaceutical products on the market in order to prevent or delay the arrival on the market of competing generic medicines – Definition of the market – Interpretation of Article 19 of Regulation (EEC) No 1786/92 concerning the creation of a supplementary protection certificate for medicinal products

Systematic classification scheme

1.
4 Internal policy of the European Union
  4.08 Competition
    4.08.02 Dominant position
      4.08.02.02 Determination of the relevant market
        4.08.02.02.01 Product or products constituting a market
3 Legal proceedings
  3.10 Appeals
    3.10.06 Pleas in law
4 Internal policy of the European Union
  4.08 Competition
    4.08.02 Dominant position
      4.08.02.04 Abuse of a dominant position
        4.08.02.04.01 Definition of abuse
4 Internal policy of the European Union
  4.08 Competition
    4.08.02 Dominant position
      4.08.02.04 Abuse of a dominant position
        4.08.02.04.02 Examples of abuse
4 Internal policy of the European Union
  4.08 Competition
    4.08.02 Dominant position
      4.08.02.04 Abuse of a dominant position
        4.08.02.04.01 Definition of abuse
3 Legal proceedings
  3.10 Appeals
    3.10.06 Pleas in law
4 Internal policy of the European Union
  4.08 Competition
    4.08.02 Dominant position
      4.08.02.04 Abuse of a dominant position
        4.08.02.04.02 Examples of abuse
3 Legal proceedings
  3.10 Appeals
    3.10.00 General
4 Internal policy of the European Union
  4.08 Competition
    4.08.03 Implementation of the competition rules
      4.08.03.03 Fines imposed by the Commission
        4.08.03.03.04 Fines for infringement of Articles 101 TFEU and 102 TFEU (Articles 81 EC and 82 EC)
          4.08.03.03.04.02 Basic amount
            4.08.03.03.04.02.02 Basic amount according to the 1998 Guidelines
              4.08.03.03.04.02.02.01 General starting amount
                4.08.03.03.04.02.02.01.01 Nature of the infringement
                  4.08.03.03.04.02.02.01.01.00 General
4 Internal policy of the European Union
  4.08 Competition
    4.08.02 Dominant position
      4.08.02.03 Criteria for establishing the existence of a dominant position
4 Internal policy of the European Union
  4.08 Competition
    4.08.02 Dominant position
      4.08.02.03 Criteria for establishing the existence of a dominant position


Citations of case-law or legislation

References in grounds of judgment

Operative part

Opinion


Dates

Date of the lodging of the application initiating proceedings

  • 15/09/2010

Date of the Opinion

  • 15/05/2012

Date of the hearing

Information not available

Date of delivery

06/12/2012


References

Publication in the Official Journal

Application: OJ C 301 from 06.11.2010, p.18

Judgment: OJ C 26 from 26.01.2013, p.2

Name of the parties

AstraZeneca v Commisson

Notes on Academic Writings

  1. Dieny, Emmanuel: Arrêt AstraZeneca : un pas trop loin dans la prise en compte des effets des abus de position dominante ?, La Semaine Juridique - entreprise et affaires 2013 nº 3 p.35-37 (FR)
  2. Idot, Laurence: Abus de position dominante dans le secteur pharmaceutique. La Cour confirme que le détournement de procédures réglementaires pour retarder l'entrée de génériques sur le marché peut être constitutif d'abus, Europe 2013 Février Comm. nº 2 p.37-38 (FR)
  3. Batchelor, Bill ; Healy, Melissa: The AstraZeneca judgment. The EU Court of justice reins in the General Court, Competition Law Insight 2013 Vol. 12 Issue 1 p.9-10 (EN)
  4. Batchelor, Bill ; Hearly, Melissa: CJUE AstraZeneca Judgment: Groping Towards a Test for Patent Office Dealings, European Competition Law Review 2013 p.171-173 (EN)
  5. Schrijvershof, D.W.L.A.: Mededingingsrecht in de geneesmiddelensector: zaak C-457/10 P, AstraZeneca/Commissie & de FTC als amicus curiae in Mylan Pharmaceuticals/Warner Chilcott, Tijdschrift Mededingingsrecht in de Praktijk 2013 p.13-26 (NL)
  6. Oude Elferink, E. ; Nieuwmeyer, R.N.A.: Het arrest van het Hof van Justitie in de zaak AstraZeneca: een beoordeling ‘on the merits’, Nederlands tijdschrift voor Europees recht 2013 p.14-23 (NL)
  7. Seitz, Claudia: Klare Grenzlinie und Minenfeld - Die Marktmissbrauchskontrolle im Arzneimittelsektor nach dem AstraZeneca-Urteil des EuGH, Europäische Zeitschrift für Wirtschaftsrecht 2013 p.377-380 (DE)
  8. Besen, Marc: EuGH: "AstraZeneca"-Entscheidung des EuGH: Konsequenzen für die Missbrauchskontrolle, Gewerblicher Rechtsschutz und Urheberrecht PRAX 2013 p.33-34 (DE)
  9. Speyart, Herman: Intellectuele eigendom & Reclamerecht 2013 p.189-192 (NL)
  10. Robin, Catherine: Déclarations trompeuses et manoeuvres pour retarder l'entrée des médicaments génériques sur le marché, Revue Lamy de la Concurrence : droit, économie, régulation 2013 nº 35 p.30-31 (FR)
  11. Van Malleghem, Pieter-Augustijn ; Devroe, Wouter: Astrazeneca: Court of Justice Upholds First Decision Finding Abuse of Dominant Position in Pharmaceutical Sector, Journal of European Competition Law & Practice 2013 Vol. 4 nº 3 p.228-232 (EN)
  12. Giannino, Michele: The EU Court of Justice Upholds the AstraZeneca Condemnation for Misusing Patent Law Procedures, Journal of European Competition Law & Practice 2013 Vol. 4 nº 4 p.317-319 (EN)
  13. Massimino, Fausto: Farmaci, posizione dominante e concorrenza sui meriti: quale bilanciamento per la Corte di giustizia?, Diritto pubblico comparato ed europeo 2013 p.677-684 (IT)
  14. Colangelo, Margherita: Concorrenza e proprietà intellettuale nel settore farmaceutico in Europa dopo il caso AstraZeneca, Giurisprudenza commerciale 2013 II p.585-602 (IT)
  15. Noti, K.: La jurisprudence de la Cour de justice et du Tribunal de l'Union européenne. Chronique des arrêts. Arrêt « AstraZeneca », Revue du droit de l'Union européenne 2013 nº 3 p.533-540 (FR)
  16. Lidgard, Hans Henrik: Mål C-457/10 P, AstraZeneca, Europarättslig tidskrift 2013 Nr 3 p.570-584 (SV)
  17. Nagy, Aranka Dóra: Nem kifizetődő a hatóságok félrevezetése – összefoglaló az AstraZeneca-ügyről, Versenytükör 2013 1. szám p.45-53 (HU)
  18. Podszun, Rupprecht: Can competition law repair patent law and administrative procedures? AstraZeneca, Common Market Law Review 2014 p.281-294 (EN)
  19. Spillmann, Adrian: Transparency obligation for holders of EU IP assets in the pharmaceutical industry, Gewerblicher Rechtsschutz und Urheberrecht INT 2014 p.315-320 (EN)
  20. Spillmann, Adrian: Transparency obligation for holders of EU IP assets in the pharmaceutical industry, Journal of Intellectual Property Law and Practice 2014 p.125-132 (EN)
  21. Govaere, Inge ; Demedts, Valerie: Towards an "Ex Ante" or Preventive Application of Article 102 TFUE in the Commission 's Policy Pursuant to the Astrazeneca-Case, Mundi et Europae civis Liber Amicorum Jacques Steenbergen (Ed. Groep Larcier, Brussels) 2014 p.441-452 (EN)
  22. Braun, Ellen: Ellen Braun über AstraZeneca: Behinderung des Marktzutritts von Generika und Erschwerung des Parallelhandels : EuGH, Urteil vom 06.12.2012 – C-457/10 P – AstraZeneca/Kommission, Wirtschaft und Wettbewerb 2021 p. 462-465 (DE)



Procedural Analysis Information

Source of the question referred for a preliminary ruling

Information not available

Subject-matter

  • Competition

Provisions of national law referred to

Information not available

Provisions of international law referred to

Information not available

Procedure and result

  • Actions for annulment
  • Appeals : dismissal on grounds of inadmissibility
  • Appeals : dismissal on substantive grounds

Formation of the Court

première chambre (Cour)

Judge-Rapporteur

Ilešič

Advocate General

Mazák

Language(s) of the Case

  • English

Language(s) of the Opinion

  • English